In a report released on November 7, Jailendra Singh from Truist Financial maintained a Hold rating on Hims & Hers Health (HIMS – Research Report), with a price target of $10.00. The company’s shares closed yesterday at $7.02.
Singh covers the Healthcare sector, focusing on stocks such as NextGen Healthcare, Evolent Health, and R1 RCM. According to TipRanks, Singh has an average return of -17.0% and a 25.81% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Hims & Hers Health with a $11.13 average price target, a 58.55% upside from current levels. In a report released on November 7, Piper Sandler also reiterated a Hold rating on the stock with a $7.00 price target.
See today’s best-performing stocks on TipRanks >>
Based on Hims & Hers Health’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $207.91 million and a GAAP net loss of $7.16 million. In comparison, last year the company earned a revenue of $144.84 million and had a GAAP net loss of $18.84 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Hims & Hers Health (HIMS) Company Description:
Oaktree Acquisition Corp. is an emerging growth company, which engages in the provision of merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company was founded by Patrick McCaney, Alexander Taubman and Mathew Pendo in 2019 and is headquartered in Los Angeles, CA.
Read More on HIMS:
